These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27928647)

  • 1. Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.
    Kumar P; Lakshmi YS; Kondapi AK
    Pharm Res; 2017 Feb; 34(2):257-268. PubMed ID: 27928647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.
    Kumar P; Lakshmi YS; Kondapi AK
    HIV Med; 2017 Aug; 18(7):452-462. PubMed ID: 28000390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats.
    Kumar P; Lakshmi YS; C B; Golla K; Kondapi AK
    PLoS One; 2015; 10(10):e0140399. PubMed ID: 26461917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles.
    Lakshmi YS; Kumar P; Kishore G; Bhaskar C; Kondapi AK
    Sci Rep; 2016 May; 6():25479. PubMed ID: 27151598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies of lamivudine-zidovudine nanoparticles for the selective uptake by macrophages.
    Sankar V; Nareshkumar PN; Ajitkumar GN; Penmetsa SD; Hariharan S
    Curr Drug Deliv; 2012 Sep; 9(5):506-14. PubMed ID: 22452408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
    Kuritzkes DR; Ribaudo HJ; Squires KE; Koletar SL; Santana J; Riddler SA; Reichman R; Shikuma C; Meyer WA; Klingman KL; Gulick RM;
    J Infect Dis; 2007 Apr; 195(8):1169-76. PubMed ID: 17357053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study.
    Ahmed F; Kumari S; Kondapi AK
    Pharm Res; 2018 Jul; 35(9):178. PubMed ID: 30014319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adherence, pharmacokinetic "tolerance capacity" and HIV resistance development].
    Mossdorf E; Hirsch HH
    Praxis (Bern 1994); 2006 Aug; 95(33):1237-9. PubMed ID: 16939126
    [No Abstract]   [Full Text] [Related]  

  • 13. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
    Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
    J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment.
    Öztürk AA; Namlı İ; Güleç K; Görgülü Ş
    Comb Chem High Throughput Screen; 2020; 23(10):1064-1079. PubMed ID: 32209039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
    Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
    Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine.
    Mishra D; Jain N; Rajoriya V; Jain AK
    J Pharm Pharmacol; 2014 Aug; 66(8):1082-93. PubMed ID: 24641311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
    Lamorde M; Schapiro JM; Burger D; Back DJ
    AIDS; 2014 Nov; 28(17):2551-63. PubMed ID: 25574958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.